RGTLF Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EDT
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.15
Previous CloseN/A
Volume17.00
Average Volume (3M)0.00
Market Cap
$2.63M
Enterprise Value$12.72M
Total Cash (Recent Filing)$141.46K
Total Debt (Recent Filing)$9.59M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding117,859,580
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.33
Price to Sales (P/S)19.37
P/FCF Ratio-0.78
Enterprise Value/Market Cap4.83
Enterprise Value/Revenue78.91
Enterprise Value/Gross Profit-62.28
Enterprise Value/Ebitda-1.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty Pharmaceutical FocusThe company operates in specialty pharmaceuticals, with activities spanning development, regulatory pathways, manufacturing, distribution, and licensed brands. This focused model can support differentiated products and regulatory expertise, although commercial scale remains important for translating that positioning into durable returns.
Improved Operating Cash BurnThe substantial reduction in operating cash outflow indicates some improvement in cash discipline or operating performance compared with the prior year. While cash generation remains negative, a narrower burn rate could extend financial runway and reduce the pace at which external funding is required.
Historical Gross-profit CapabilityPositive gross profit through 2025 shows that the company has previously generated revenue above reported cost of sales. That history provides evidence of underlying commercial potential, even though the 2026 reversal means the capability has not yet proven durable under current operating conditions.
Bears Say
Sharp Revenue DeteriorationA severe revenue contraction following several years of declines signals weakening commercial traction and reduces the scale available to support research, regulatory, and distribution activities. Unless revenue stabilizes, the company will have less operating leverage and a weaker foundation for sustainable growth.
Negative Equity And High LeverageNegative equity and debt substantially exceeding the asset base indicate a materially weakened balance sheet. This reduces the cushion available to creditors and shareholders, limits financial flexibility, and increases refinancing risk while making it harder to fund development or absorb further operating losses.
Persistent Cash Burn And Deep LossesPersistent operating cash outflows combined with a deeply negative net margin show that the current business is not self-funding. Continued losses can consume liquidity, increase reliance on external capital, and constrain investment in products, regulatory programs, and commercialization over the coming quarters.
Argent Biopharma News
RGTLF FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is $2.63M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Mar 03, 2027 which is in 129 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -$0.027 earnings per share for the quarter.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 117,859,580 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -$0.027 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in RGTLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
RGTLF Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
102.60%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Argent Biopharma
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―